{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-191859","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2023-07-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.756083+00:00","generated_at":"2026-06-13T04:16:07.407355+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Verrica FDA approves YCANTH for molluscum; secures up to $125M debt financing","bullets":["YCANTH (cantharidin 0.7%) topical solution approved for molluscum contagiosum in patients 2+ years; first FDA-approved treatment for the indication.","Phase 3 CAMP-1: 46% complete clearance vs 18% placebo (p<0.0001); CAMP-2: 54% vs 13% (p<0.0001).","Non-binding term sheet for up to $125M debt facility; $50M available immediately at close, expected by end of week.","Debt is 5-year term loan bearing SOFR + 8% (4% floor); warrant for $3.1M common stock at 10-day VWAP.","Verrica plans commercial launch by September 2023; cash runway extended into Q1 2025 with $60M on hand plus $50M upfront."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-191859","json":"https://secwatch.observer/filing/0001193125-23-191859.json","markdown":"https://secwatch.observer/filing/0001193125-23-191859.md","text":"https://secwatch.observer/filing/0001193125-23-191859.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312523191859/0001193125-23-191859-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312523191859/d542791d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T04:16:07.407355+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}